Backed by the likes of Johnson & Johnson and Mayo Clinic, Nevro Corp. has raised $58 million to prepare for a hoped-for U.S. launch of its spinal cord stimulator for chronic pain, according to a report by Mass Device.
The recent round of $58 million in Series B financing was led by Johnson & Johnson Development Corp. and includes Mayo Clinic.
In 2010, the Nevro device received CE mark approval in Europe for chronic leg and back pain.
Read the Mass Device report on Nevro.
Related Articles on Pain Management Devices:
Medtronic Issues Warning for SynchroMed II Implantable Painkiller Pumps
Impact on Pain Management of the New Outcomes Research Institute: Q&A With Dr. Laxmaiah Manchikanti
NIH Identifies 4 Key Areas for Record Amount of Pain Research Funding